THE COST-EFFECTIVENESS OF HIV TESTING OF PHYSICIANS AND DENTISTS IN THE UNITED-STATES

被引:28
|
作者
PHILLIPS, KA
LOWE, RA
KAHN, JG
LURIE, P
AVINS, AL
CICCARONE, D
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA
[4] UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA
来源
关键词
D O I
10.1001/jama.271.11.851
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To evaluate the cost-effectiveness of alternative policies for human immunodeficiency testing (HIV) testing of physicians and dentists. Methods.-Decision analysis and cost-effectiveness analysis from a societal perspective were used. Data were derived from extensive literature review and consultation with experts. We conducted sensitivity analyses and also performed a cost-benefit analysis. Analyses.-We analyzed policies for mandatory or voluntary testing of all physicians, surgeons, and dentists; for those testing positive, we analyzed mandatory or voluntary exclusion from practice, restriction from performance of invasive procedures, or requirements to inform patients of serostatus. Main Outcome Measure.-Cost per patient infection averted. Results.-Although one-time mandatory testing of surgeons and dentists with mandatory restriction of those found to be HIV-positive is more cost-effective than other policies, the cost-effectiveness varies tremendously under different scenarios. Results were highly sensitive to several data inputs, especially HIV seroprevalence of surgeons and dentists and transmission risk. For example, under a medium seroprevalence and transmission risk scenario, mandatory testing of all surgeons might avert 25 infections at a total cost of $27.9 million or $1 115 000 per infection averted and an incremental cost of $291 000 compared with current testing; however, the incremental cost-effectiveness per patient infection averted ranges from $29 807 000 under a low-risk scenario to a savings of $81 000 under a high-risk scenario. Conclusion.-Our analysis neither justifies nor precludes a mandatory testing policy. Further research on the key data inputs is needed. Given the ethical, social, and public health implications, mandatory testing policies should not be implemented without greater certainty as to their cost-effectiveness.
引用
收藏
页码:851 / 858
页数:8
相关论文
共 50 条
  • [41] The cost-effectiveness of expanded testing for primary HIV infection
    Coco, A
    ANNALS OF FAMILY MEDICINE, 2005, 3 (05) : 391 - 399
  • [42] The Cost-Effectiveness of HIV Voluntary Counseling and Testing in China
    Wang, Shuhong
    Moss, John R.
    Hiller, Janet E.
    ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2011, 23 (04) : 620 - 633
  • [43] Cost-effectiveness of HIV counseling and testing in US prisons
    Beena Varghese
    Thomas A. Peterman
    Journal of Urban Health, 2001, 78 : 304 - 312
  • [44] Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States
    Chaudhary, Mohammad A.
    Lubinga, Solomon J.
    Smare, Caitlin
    Hertel, Nadine
    Penrod, John R.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (08): : E254 - +
  • [45] Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
    Jieling Chen
    Megan A. O’Brien
    H. Keri Yang
    John D. Grabenstein
    Erik J. Dasbach
    Advances in Therapy, 2014, 31 : 392 - 409
  • [46] Cost-effectiveness analysis of contraceptives available in United States
    Trussell, J.
    Lalla, A. M.
    Doan, Q., V
    Reyes, E.
    Pinto, L.
    Gricar, J. A.
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A248
  • [47] COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINES FOR ADULTS IN THE UNITED STATES
    Yang, H. K.
    Chen, J.
    O'Brien, M.
    Grabenstein, J.
    Dasbach, E.
    VALUE IN HEALTH, 2013, 16 (03) : A93 - A93
  • [48] Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
    Chen, Jieling
    O'Brien, Megan A.
    Yang, H. Keri
    Grabenstein, John D.
    Dasbach, Erik J.
    ADVANCES IN THERAPY, 2014, 31 (04) : 392 - 409
  • [49] Update on and correction to the cost-effectiveness of contraceptives in the United States
    Trussell, James
    CONTRACEPTION, 2012, 85 (06) : 611 - 611
  • [50] Cost-effectiveness analysis of contraceptives available in the United States
    Trussell, J.
    Lalla, A.
    Pinto, L.
    Gricar, J.
    CONTRACEPTION, 2008, 78 (02) : 177 - 178